clinical trial · NCT02612311
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaObinutuzumabUblituximabTGR-1202Chlorambucil
brief summary
This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) participants.
started
Nov 19, 2015
primary completion
Feb 22, 2023
completion
Feb 22, 2023
last updated
Dec 13, 2024
official title
Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol